{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:32:16Z","timestamp":1772191936158,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.biopsych.2006.10.005","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T12:19:43Z","timestamp":1169036383000},"page":"635-641","source":"Crossref","is-referenced-by-count":111,"title":["CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial"],"prefix":"10.1016","volume":"62","author":[{"given":"Anna M.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Jepson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Hawk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn","family":"Lerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel F.","family":"Tyndale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2006.10.005_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pscychresns.2003.12.006","article-title":"Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: A preliminary study","volume":"130","author":"Brody","year":"2004","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2006.10.005_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/dmd.104.001107","article-title":"Haplotype structure and allele frequencies of CYP2B6 in a Korean population","volume":"32","author":"Cho","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.biopsych.2006.10.005_bib3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/mol.104.001313","article-title":"Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors","volume":"66","author":"Damaj","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2006.10.005_bib4","first-page":"1222","article-title":"Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity","volume":"28","author":"Faucette","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.biopsych.2006.10.005_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00008571-199906000-00004","article-title":"Human CYP2B6: Expression, inducibility and catalytic activities","volume":"9","author":"Gervot","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib5a","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2006.10.005_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1469-1809.2000.6450383.x","article-title":"The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit","volume":"64","author":"Gu","year":"2000","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.biopsych.2006.10.005_bib7","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.biopsych.2006.10.005_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","article-title":"Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes","volume":"14","author":"Hesse","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00008571-200111000-00007","article-title":"Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19","volume":"11","author":"Hoffman","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/j.1552-4604.1997.tb04361.x","article-title":"Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers","volume":"37","author":"Hsyu","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2006.10.005_bib11","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","author":"Hughes","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biopsych.2006.10.005_bib12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199710233371703","article-title":"A comparison of sustained-release bupropion and placebo for smoking cessation","volume":"337","author":"Hurt","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2006.10.005_bib13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0006-2952(96)00052-4","article-title":"Multiple forms of human P450 expressed in Saccharomyces cerevisiae","volume":"51","author":"Imaoka","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopsych.2006.10.005_bib14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1373\/clinchem.2004.031708","article-title":"Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping","volume":"50","author":"Jacob","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.biopsych.2006.10.005_bib15","first-page":"415","article-title":"Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations","volume":"143","author":"Jefferson","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.biopsych.2006.10.005_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.31.4.398","article-title":"Functional characterization of cytochrome P450 2B6 allelic variants","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.biopsych.2006.10.005_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199903043400903","article-title":"A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation","volume":"340","author":"Jorenby","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2006.10.005_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","article-title":"Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz","volume":"15","author":"Klein","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: Demonstration of phenotypic null alleles","volume":"311","author":"Lang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.10.005_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008571-200211000-00007","article-title":"Pharmacogenetic investigation of smoking cessation treatment","volume":"12","author":"Lerman","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.npp.1300861","article-title":"Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials","volume":"31","author":"Lerman","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2006.10.005_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clpt.2006.03.010","article-title":"Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity","volume":"80","author":"Loboz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2006.10.005_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clpt.2004.10.011","article-title":"Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence","volume":"77","author":"Malaiyandi","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2006.10.005_bib26","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0022-3565(24)36947-2","article-title":"A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes","volume":"282","author":"Messina","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.10.005_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0028-3908(03)00136-9","article-title":"Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain","volume":"45","author":"Miksys","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2006.10.005_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00008571-200409000-00006","article-title":"Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians","volume":"14","author":"Schoedel","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2006.10.005_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s002130050022","article-title":"The effect of bupropion on nicotine craving and withdrawal","volume":"148","author":"Shiffman","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2006.10.005_bib32","first-page":"321","article-title":"Bupropion is a nicotinic antagonist","volume":"295","author":"Slemmer","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.10.005_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14622200210123581","article-title":"Biochemical verification of tobacco use and cessation","volume":"4","year":"2002","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.biopsych.2006.10.005_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4088\/PCC.v06n0403","article-title":"A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor","volume":"6","author":"Stahl","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2006.10.005_bib35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14622200310001646903","article-title":"Bupropion SR and counseling for smoking cessation in actual practice: Predictors of outcome","volume":"5","author":"Swan","year":"2003","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.biopsych.2006.10.005_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-005-0145-x","article-title":"Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h","volume":"183","author":"Teneggi","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2006.10.005_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1365-2796.2003.01185.x","article-title":"A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation","volume":"254","author":"Tonnesen","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.biopsych.2006.10.005_bib38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopsych.2006.10.005_bib39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/00498258709043939","article-title":"Pharmacological significance of the species differences in bupropion metabolism","volume":"17","author":"Welch","year":"1987","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopsych.2006.10.005_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.tpj.6500157","article-title":"Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation","volume":"3","author":"Xie","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.biopsych.2006.10.005_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1006\/bbrc.2001.6209","article-title":"An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles","volume":"290","author":"Xu","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopsych.2006.10.005_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002040050588","article-title":"Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes","volume":"73","author":"Yamazaki","year":"1999","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.biopsych.2006.10.005_bib43","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1124\/mol.104.008086","article-title":"A natural CYP2B6 TATA box polymorphism (\u221282T\u2192 C) leading to enhanced transcription and relocation of the transcriptional start site","volume":"67","author":"Zukunft","year":"2005","journal-title":"Mol Pharmacol"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322306012686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322306012686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T01:18:00Z","timestamp":1736731080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322306012686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0006322306012686"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2006.10.005","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}